Xceleron
Germantown
About Xceleron
Xceleron believes that AMS technology and our expertise can get life-changing products quickly and cost-effectively to people who need them. We work with integrity and an open mind and are driven by science and the spirit of collaboration. Founded in 1997 in York, UK, and now headquartered in Germantown, Maryland, Xceleron pioneered human microdose and microtracer techniques using AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I, and Phase II/III clinical trials. Xceleron’s experience is especially valuable because the characteristics of many contemporary small molecules (low solubility, long half-life and disproportionate human metabolites) mean that their early pharmacokinetic and metabolic characterization is critical to the cost-effectiveness of clinical development.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $10.1M
- Funding stage: M&A
- Last round: Series Unknown (Feb 2012)
- Website: xceleron.com
- Phone: +1 240 361-1900
Industries & Categories
Analytics, Biotechnology, Medical
Social Profiles
Canonical: https://fsome.com/organization/xceleron-2444296 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.